A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 0
- Population
- ALL · 50 Years to 80 Years
- Duration
- Not reported
- Intervention
- Bevacizumab; Ranibizumab
- Comparator
- Lucentis®
- Outcomes measured
- • Proportion of patients losing fewer than 15 letters on EDTRS chart at month 12 — week 52; • Frequency of ocular and systemic adverse events (AE) and serious adverse events (SAE) that are related, in Investigat…; • Frequency of AE and SAE with toxicity level of 3-4 that are related, in Investigator's opinion, to AMD therapy — week…; • Number of cases of early withdrawal from the study caused by AE or SAE — week 52; • Number of patients who have binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 1…; • The mean titer of binding and neutralizing antibodies to BCD-021/Lucentis in serum at screening and month 12 — screen…; • Mean change in VA score, measured on the EDTRS scale at month 12 — week 52; • Average number of injections and time before re-injection — week 52; • Lesion size at month 6 and month 12 (by angiography) — week 26, 52; • Lesion leakage at month 6 and month 12 — week 26, 52; • Change in fluid and foveal thickness on OCT during the study — week 52; • Retinal sensitivity measured by microperimetry at screening, at month 6 and month 12 — screening, week 26, 52; • Timing of visual improvement after initiation of therapy — week 52
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.